1. Monoclonal Gammopathy of Undetermined Significance
Ronald S. Go, MD, Herbert C. Heien, MS, Lindsey R. Sangaralingham, MPH, Elizabeth B. Habermann, PhD, Nilay D. Shah, PhD 
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  
Volume 1, Issue 2, Pages (September 2017)
DOI: /j.mayocpiqo
Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Figure 1
Mean interval of monoclonal gammopathy of undetermined significance follow-up. A, Changes in overall follow-up patterns over time. B, Follow-up patterns according to sex, race/ethnicity, age, and US geographic region.
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2017 1, DOI: ( /j.mayocpiqo )
Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

3. Figure 2
Tests ordered during monoclonal gammopathy of undetermined significance (MGUS) follow-up. A, Frequency of specific tests ordered. B, Frequency of the more common test combinations is shown above the bars, which show the combinations of tests performed during follow-up. The MGUS-specific tests include free light chain (FLC) studies, immunofixation (IFX), skeletal survey, serum protein electrophoresis (SPEP), or urine protein electrophoresis (UPEP). CBC = complete blood cell.
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2017 1, DOI: ( /j.mayocpiqo )
Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

4. Figure 3
Concordance of monoclonal gammopathy of undetermined significance follow-up with current guidelines. EMN = European Myeloma Network; IEC = international expert consensus; IMWG = International Myeloma Working Group; UK-Nordic = UK Myeloma Forum and Nordic Myeloma Study Group.
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2017 1, DOI: ( /j.mayocpiqo )
Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions